Our technology has been validated in multiple vaccine and therapeutic product categories, and iBio is developing a proprietary therapeutic product, IBIO-CFB03, for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and other fibrotic diseases in collaboration with Dr. Feghali-Bostwick at the Medical University of South Carolina. Data published in 2012 by Dr. Feghali-Bostwick demonstrate that specific endostatin-derived peptides are useful for both in inhibition and reversal of fibrosis in preclinical mouse models of fibrosis as well as in human skin. iBio has produced the active pharmaceutical ingredient using its patented iBioLaunch™ technology and has made the clinical development of this promising product a key priority.
IPF is a life-shortening lung disease with a rapidly progressing negative impact on quality of life leading to death within an average of three to five years after diagnosis. IPF has a worse survival rate than most cancers except for pancreatic cancer and certain lung cancers.
Systemic sclerosis is a disorder that affects connective tissue of skin and internal organs as well as the walls of blood vessels. Early diagnosis and individualized therapy can be helpful, but treatment of systemic sclerosis is limited to symptom management. No currently approved drug has been proven to arrest the underlying process or processes that drive progression of the disease.
Organ fibrosis is responsible for health care costs exceeding $10 billion per year, and the number of deaths due to fibrosis is estimated to be double those due to cancer. Organ fibrosis is responsible for nearly half of deaths in developed countries and results in significant physical, emotional, and financial burdens as well.
iBio has demonstrated the feasibility of developing and producing a wide range of products that are available for license along with the technology to bring them to patients.
Our technology has been validated across a wide range of applications in both vaccines and biotherapeutics, and these products are available for license along with the technology to bring innovative medicines to patients.